Other News To Note
Compugen Ltd., of Tel Aviv, Israel, said it demonstrated the therapeutic potential of CGEN-15022, a B7/CD28-like membrane protein, as an immune checkpoint target in multiple cancers. The company's results suggested CGEN-15022 is expressed in numerous types of epithelial cancers, including liver, colorectal, lung and ovarian cancers.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter